FDA has lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial in hereditary transthyretin amyloidosis with polyneuropathy. The decision allows the late stage study of Intellia's ...

Please provide your email address to receive an email when new articles are posted on . Wainua has received regulatory approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct diagnosis.

Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.

Since 1995 I have had the interesting experience of working as a neurologist in a large state prison whose primary mission is to provide medical care to inmates. A large proportion of my practice ...

– EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo – CARLSBAD, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among adults with type 2 diabetes, those reporting ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin amyloidosis with polyneuropathy. Polyneuropathy stages and disability scores were ...

Hereditary transthyretin amyloidosis (hATTR) is a rare inherited disorder that gets worse over time. It often affects the nerves, heart, liver, and kidneys, but it can also affect other organs.

Patisiran continued to demonstrate benefit in hATTR with polyneuropathy at 5 years. Measures of disability, polyneuropathy, and quality of life showed modest changes. This is the longest study of an ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI. CIDP ...